URGN Q3 2025 Earnings — UroGen Pharma Ltd. Revenue & Financial Results | Market Cap Arena

URGNUroGen Pharma Ltd.

$927M

Q3 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$27M+9.0% YoY

Gross Profit

$24M88.1% margin

Operating Income

-$27M-99.7% margin

Net Income

-$33M-121.3% margin

EPS (Diluted)

$-0.69

QoQ Revenue Growth

+13.5%

Cash Flow

Operating Cash Flow

-$42M

Free Cash Flow

-$42M

Stock-Based Comp.

$3M

Balance Sheet

Total Assets

$185M

Total Liabilities

$300M

Stockholders' Equity

-$115M

Cash & Equivalents

$90M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$27M	$25M	+9.0%
Gross Profit	$24M	$23M	+6.4%
Operating Income	-$27M	-$18M	-56.1%
Net Income	-$33M	-$24M	-40.9%

Revenue Segments

Jelmyto

$26M100%